The FSHD1 Optical Genome Mapping Test (OGM) is advanced diagnostic tool that uses technology to provide a comprehensive and accurate assessment of genetic changes in patients with FSHD1
Ahead of the Rare Disease Day, MedGenome Labs has announced the launch of Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) test in India.
MedGenome Labs is the first commercial lab to offer this new genetic test that will help individuals with FSHD1 to get an early and accurate diagnosis, leading to improved disease management options.
The FSHD1 Optical Genome Mapping Test (OGM) is advanced diagnostic tool that uses technology to provide a comprehensive and accurate assessment of genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1.
Vedam Ramprasad, PhD, CEO (India), MedGenome Labs commented on the launch, saying “As a company dedicated to improving patient care through genetics, we are thrilled to be the first in India to offer the Optical Genome Mapping Test for FSHD1. This is a significant step forward in our mission to provide the highest quality genetic testing services to clinicians and healthcare providers across the country. The launch of this new test represents a major milestone in the diagnosis and management of FSHD1 in India.”
Sakthivel Murugan SM, Vice President – Lab Operations, MedGenome Labs said, “As a physician, I understand the challenges and concerns that patients with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) face. With the launch of the FSHD1 test in India, we are proud to offer patients a reliable and accurate diagnostic tool that will allow for early detection and personalised treatment plans. This test is a critical step forward in advancing precision medicine in India.”
- Advertisement -